APA (7th ed.) Citation

Geva, M., Reilmann, R., Schubert, R., Chen, K., Goldberg, Y. P., & Hayden, M. R. In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease. Elsevier.

Chicago Style (17th ed.) Citation

Geva, Michal, Ralf Reilmann, Robin Schubert, Kelly Chen, Y Paul Goldberg, and Michael R. Hayden. In the Phase 3 PROOF-HD Trial, Pridopidine Shows Consistent Motor Function Improvements in Q-Motor Measures, Supporting Q-Motor as a Predictive Measure of Long-term Functional Benefit and Slower Progression (cUHDRS) in Huntington Disease. Elsevier.

MLA (9th ed.) Citation

Geva, Michal, et al. In the Phase 3 PROOF-HD Trial, Pridopidine Shows Consistent Motor Function Improvements in Q-Motor Measures, Supporting Q-Motor as a Predictive Measure of Long-term Functional Benefit and Slower Progression (cUHDRS) in Huntington Disease. Elsevier.